These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21613849)

  • 21. A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade.
    Langleben D; Cacoub P
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():27-31. PubMed ID: 19335744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
    Don GW; Joseph F; Celermajer DS; Corte TJ
    Intern Med J; 2012 Dec; 42(12):1351-4. PubMed ID: 23253000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sitaxsentan: a novel endothelin-A receptor antagonist for pulmonary arterial hypertension.
    Widlitz AC; Barst RJ; Horn EM
    Expert Rev Cardiovasc Ther; 2005 Nov; 3(6):985-91. PubMed ID: 16292989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney.
    Dhaun N; MacIntyre IM; Bellamy CO; Kluth DC
    Am J Kidney Dis; 2009 Oct; 54(4):726-31. PubMed ID: 19376621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sitaxentan: new drug. Pulmonary hypertension: better to continue to use bosentan.
    Prescrire Int; 2008 Jun; 17(95):108. PubMed ID: 18630348
    [No Abstract]   [Full Text] [Related]  

  • 26. Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade.
    Zacà V; Metra M; Danesi R; Lombardi C; Verzura G; Dei Cas L
    Ther Adv Respir Dis; 2009 Feb; 3(1):11-4. PubMed ID: 19293198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic administration of the endothelin-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage: dose study and review of endothelin-based therapies in the literature on cerebral vasospasm.
    Wanebo JE; Arthur AS; Louis HG; West K; Kassell NF; Lee KS; Helm GA
    Neurosurgery; 1998 Dec; 43(6):1409-17; discussion 1417-8. PubMed ID: 9848855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulmonary hypertension: basic concepts and practical management.
    Hoeper MM; Dinh-Xuan AT
    Eur Respir J; 2008 Feb; 31(2):236-7. PubMed ID: 18238945
    [No Abstract]   [Full Text] [Related]  

  • 29. Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas.
    Mucke HA
    IDrugs; 2009 Jun; 12(6):366-75. PubMed ID: 19517317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective ET(A) receptor blockade protects against cisplatin-induced acute renal failure in male rats.
    Helmy MM; Helmy MW; Abd Allah DM; Abo Zaid AM; Mohy El-Din MM
    Eur J Pharmacol; 2014 May; 730():133-9. PubMed ID: 24632086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endothelin receptor blockers in cardiovascular disease.
    Rich S; McLaughlin VV
    Circulation; 2003 Nov; 108(18):2184-90. PubMed ID: 14597580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].
    Montani D; Humbert M
    Rev Mal Respir; 2010 Feb; 27(2):103-5. PubMed ID: 20206056
    [No Abstract]   [Full Text] [Related]  

  • 33. Successful up-front combination therapy in a patient with idiopathic pulmonary hypertension and patent foramen ovale: an alternative to epoprostenol therapy?
    Pitsiou GG; Chavouzis N; Nakou C; Boutou AK; Argyropoulou P; Stanopoulos I
    J Heart Lung Transplant; 2009 Jun; 28(6):651-3. PubMed ID: 19481029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].
    Hoeper MM
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S308-10. PubMed ID: 17139593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An evidence-based approach to the management of pulmonary arterial hypertension.
    Coyne TC
    Curr Opin Cardiol; 2006 Sep; 21(5):526; author reply 526-7. PubMed ID: 16900019
    [No Abstract]   [Full Text] [Related]  

  • 36. Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension.
    Lee WT; Kirkham N; Johnson MK; Lordan JL; Fisher AJ; Peacock AJ
    Eur Respir J; 2011 Feb; 37(2):472-4. PubMed ID: 21282815
    [No Abstract]   [Full Text] [Related]  

  • 37. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
    Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L
    Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sitaxsentan for the prevention of experimental shunt-induced pulmonary hypertension.
    Rondelet B; Kerbaul F; Vivian GF; Hubloue I; Huez S; Fesler P; Remmelink M; Brimiouille S; Salmon I; Naeije R
    Pediatr Res; 2007 Mar; 61(3):284-8. PubMed ID: 17314684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulmonary hypertension in older children: new approaches and therapies.
    Abman SH
    Paediatr Respir Rev; 2006; 7 Suppl 1():S177-9. PubMed ID: 16798555
    [No Abstract]   [Full Text] [Related]  

  • 40. Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan.
    Faruqi S; Fathi H; Morice AH
    Int J Cardiol; 2010 Oct; 144(3):e43-5. PubMed ID: 19171388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.